Zhejiang Taimei Medical Technology Co., Ltd. (“Taimei Tech”) disclosed that it repurchased 20,000 H shares on 23 September 2026 through the Hong Kong Stock Exchange. The buyback was executed at prices ranging from HKD 4.74 to HKD 5.04 per share, with a volume-weighted average repurchase price of HKD 4.96, resulting in a total outlay of HKD 0.10 million.

Post-transaction, the number of issued shares excluding treasury shares fell from 193.35 million to 193.33 million, while treasury shares increased to 7.26 million. Total issued shares remained unchanged at 200.59 million. The latest buyback equates to 0.01% of the company’s outstanding share capital.

The repurchase formed part of the mandate approved by shareholders on 23 June 2026, which authorises Taimei Tech to buy back up to 20.02 million shares. Including the latest transaction, 6.84 million shares—equivalent to 3.42% of the share base on the mandate date—have been repurchased under this authority.

A moratorium on new share issuance or disposal of treasury shares is in effect until 23 October 2026, in line with Hong Kong Listing Rules governing post-buyback activities.